Insulin aspart rapid-acting - Sanofi

Drug Profile

Insulin aspart rapid-acting - Sanofi

Alternative Names: SAR 341402

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 01 Aug 2017 Phase-III clinical trials in Type-1 diabetes mellitus (Treatment-experienced) in USA (SC) (NCT03211858)
  • 01 Aug 2017 Phase-III clinical trials in Type-2 diabetes mellitus (Treatment-experienced) in USA (SC) (NCT03211858)
  • 06 Jul 2017 Sanofi plans a phase III trial for Type-1 diabetes mellitus and Type-2 diabetes mellitus (SC) (NCT03211858)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top